Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Endo Pharmaceuticals
• Collaborator: Alkermes, Inc.
• Treatments: Trospium chloride

Criteria

Inclusion Criteria:

• Male or female COPD patients between the ages of 40 and 80 years

• Smoking history of at least 10 pack years

• Not currently using (or able to wash out of) any long acting bronchodilators

Exclusion Criteria:

• Candidate on a waiting list for surgery while on study

• Using long-term oxygen therapy

• Hospitalization for COPD exacerbation